QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction

JACC: Heart Failure

Volumn 4, Issue 6, 2016, Pages 477-486

  Joseph, Jacob ^a,b   Claggett, Brian C ^a   Anand, Inder S ^c   Fleg, Jerome L ^d   Huynh, Thao ^e   Desai, Akshay S ^a   Solomon, Scott D ^a   O'Meara, Eileen ^f   Mckinlay, Sonja ^g   Pitt, Bertram ^h   Pfeffer, Marc A ^a   Lewis, Eldrin F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e MONTREAL GENERAL HOSPITAL   (Canada)

^f MONTREAL HEART INSTITUTE   (Canada)

^g NEW ENGLAND RESEARCH INSTITUTES   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Dyssynchrony; Electrocardiogram; Heart failure with preserved ejection fraction; Outcomes

Indexed keywords

SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; FEMALE; HEART ARREST; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE CONDUCTION DISTURBANCE; HOSPITALIZATION; HUMAN; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL VARIABLE; PREDICTION; PRIORITY JOURNAL; QRS INTERVAL; RISK FACTOR; CARDIOVASCULAR DISEASE; COMPLICATION; ELECTROCARDIOGRAPHY; GEORGIA (REPUBLIC); HEART ARRHYTHMIA; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NORTH AMERICA; PATHOPHYSIOLOGY; PROGNOSIS; RUSSIAN FEDERATION; SOUTH AMERICA; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; GEORGIA (REPUBLIC); HEART ARREST; HEART FAILURE; HOSPITALIZATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MULTIVARIATE ANALYSIS; NORTH AMERICA; PROGNOSIS; RUSSIA; SOUTH AMERICA; SPIRONOLACTONE; STROKE VOLUME;

EID: 84962130478     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.02.013     Document Type: Article

References (36)

1. Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 Comprehensive heart failure practice guideline. J Card Fail 2010, 16:1-194.
2. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
3. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:147-239.
4. Shah S.J. Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter. J Am Coll Cardiol 2013, 62:1339-1342.
5. Butler J., Fonarow G.C., Zile M.R., et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. J Am Col Cardiol HF 2014, 2:97-112.
6. Shah S.J., Katz D.H., Selvaraj S., et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015, 131:269-279.
7. Xiao H.B., Roy C., Fujimoto S., Gibson D.G. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol 1996, 53:163-170.
8. Donal E., Lund L., Linde C., Daubert J.C. Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project. Arch Cardiovasc Dis 2010, 103:404-410.
9. Lund L.H., Jurga J., Edner M., et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 2013, 34:529-539.
10. Park H.S., Kim H., Park J.H., et al. QRS prolongation in the prediction of clinical cardiac events in patients with acute heart failure: analysis of data from the Korean Acute Heart Failure Registry. Cardiology 2013, 125:96-103.
11. Pitt B., Pfeffer M.A., Assmann S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014, 370:1383-1392.
12. Desai A.S., Lewis E.F., Li R., et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011, 162:966-972. e10.
13. Pfeffer M.A., Claggett B., Assmann S.F., et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015, 131:34-42.
14. Kashani A., Barold S.S. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 2005, 46:2183-2192.
15. Varadarajan P., Pai R.G. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. J Card Fail 2003, 9:107-112.
16. Hawkins N.M., Wang D., McMurray J.J., et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. Eur J Heart Fail 2007, 9:510-517.
17. Donal E., Lund L.H., Oger E., et al. Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. Arch Cardiovasc Dis 2014, 107:112-121.
18. Wang J., Kurrelmeyer K.M., Torre-Amione G., Nagueh S.F. Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy. J Am Coll Cardiol 2007, 49:88-96.
19. De Sutter J., Van de Veire N.R., Muyldermans L., et al. Prevalence of mechanical dyssynchrony in patients with heart failure and preserved left ventricular function (a report from the Belgian Multicenter Registry on dyssynchrony). Am J Cardiol 2005, 96:1543-1548.
20. Santos A.B., Kraigher-Krainer E., Bello N., et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 2014, 35:42-47.
21. Yerra L., Anavekar N., Skali H., et al. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 2006, 3:313-316.
22. Mentz R.J., Greiner M.A., DeVore A.D., et al. Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study. Circ Heart Fail 2015, 8:243-251.
23. Tribouilloy C., Rusinaru D., Mahjoub H., et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008, 29:339-347.
24. Zakeri R., Chamberlain A.M., Roger V.L., Redfield M.M. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013, 128:1085-1093.
25. Whitbeck M.G., Charnigo R.J., Shah J., et al. QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study. Europace 2014, 16:803-811.
26. Zimetbaum P.J., Buxton A.E., Batsford W., et al. Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation 2004, 110:766-769.
27. Iuliano S., Fisher S.G., Karasik P.E., Fletcher R.D., Singh S.N. QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002, 143:1085-1091.
28. Schneider J.F., Thomas H.E., Sorlie P., Kreger B.E., McNamara P.M., Kannel W.B. Comparative features of newly acquired left and right bundle branch block in the general population: the Framingham study. Am J Cardiol 1981, 47:931-940.
29. Schneider J.F., Thomas H.E., Kreger B.E., McNamara P.M., Sorlie P., Kannel W.B. Newly acquired right bundle-branch block: the Framingham Study. Ann Intern Med 1980, 92:37-44.
30. Lam C.S., Roger V.L., Rodeheffer R.J., Borlaug B.A., Enders F.T., Redfield M.M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009, 53:1119-1126.
31. Mohammed S.F., Hussain I., Abou Ezzeddine O.F., et al. Right ventricular function in heart failure with preserved ejection fraction: a community based study. Circulation 2014, 130:2310-2320.
32. Melenovsky V., Hwang S.J., Lin G., Redfield M.M., Borlaug B.A. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014, 35:3452-3462.
33. Burke M.A., Katz D.H., Beussink L., et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2014, 7:288-299.
34. Mazzoleni A., Curtin M.E., Wolff R., Reiner L., Somes G. On the relationship between heart weights, fibrosis, and QRS duration. J Electrocardiol 1975, 8:233-236.
35. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
36. Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013, 62:263-271.